Hikma Pharmaceuticals Plc

As of June 30, 2026, Hikma Pharmaceuticals Plc carries a market capitalization of 65.23B, placing it among publicly traded companies globally. Its enterprise value stands at 94.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hikma Pharmaceuticals Plc's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2026, Hikma Pharmaceuticals Plc has 210.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hikma Pharmaceuticals Plc maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 14, 2026, Hikma Pharmaceuticals Plc's stock has declined approximately 8.42% over the past 52 weeks.

As of June 30, 2026, Hikma Pharmaceuticals Plc holds 5.05B in cash and equivalents against 34.19B in total debt, resulting in a net debt position of 28.08B. Total book value stands at 44.08B, with working capital of 23.73B providing operational flexibility.